Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Allarity Therapeutics, Inc.

Ticker
ALLR
Sector
Industry
Report date
November 13, 2026
Valye AI Score

78

High visibility
Recent developments
Recent developments summary

Recent developments for Allarity Therapeutics include clinical progress with Stenoparib, patent grants, licensing agreements, initial revenue-generating deals, and financial results indicating ongoing net losses and liquidity challenges.

Recent developments:
  • Allarity Therapeutics signed its first revenue-generating CLIA services deal, marking initial commercial activity beyond clinical development [N1].
  • The company received a Japanese patent for its Stenoparib DRP companion diagnostic, providing protection through 2039 [N3].
  • Allarity recorded a net loss of $6.2 million for the quarter ended September 30, 2026, with basic EPS of -$0.39 [S1].
  • The company initiated Phase 2 dosing of Stenoparib in lung cancer and is progressing toward Phase 3 readiness [N7].
  • Licensing agreements were signed to enhance the DRP platform and support precision oncology in breast cancer [N8].
  • Cash and cash equivalents stood at $14.1 million as of September 30, 2026, with current assets of $26.9 million and current liabilities of $29.5 million, resulting in a current ratio of 0.91 and cash ratio of 0.48 [S1].
  • Negative stockholders' equity as of September 30, 2026, may affect Nasdaq listing compliance and pose delisting risks [S1].
Overview

Allarity Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company specializing in oncology drug development and companion diagnostics. Its lead product candidate, Stenoparib, is undergoing clinical trials including Phase 2 dosing in lung cancer and is advancing toward Phase 3 readiness. The company leverages its Diagnostic Response Prediction (DRP) platform to support precision oncology, with recent patent grants and licensing agreements enhancing this platform. Allarity has initiated its first revenue-generating CLIA services deal, marking a step toward commercial operations. Financially, the company reported a net loss for the quarter ended September 30, 2026, with cash and current assets slightly below current liabilities, reflecting liquidity challenges. The company also holds debt financing from Streeterville Capital with maturities in 2027. Allarity's stockholders' equity was negative as of the latest quarter, posing potential risks related to Nasdaq listing compliance.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology therapeutics and diagnostics. The company is advancing its lead drug candidate Stenoparib through clinical trials and progressing toward Phase 3 readiness. It has secured a Japanese patent for its Stenoparib DRP companion diagnostic with protection through 2039 and signed its first revenue-generating CLIA services deal. As of September 30, 2026, the company reported a net loss of $6.2 million, held $14.1 million in cash and equivalents, and had a current ratio below 1, indicating liquidity constraints. The company faces risks related to negative stockholders' equity and potential Nasdaq delisting. Recent news highlights clinical progress, licensing agreements, and financial developments [S1][N1][N3][N7].

Scenarios for ALLR

Bull case model:

The company has demonstrated progress in advancing Stenoparib through clinical trials, including Phase 2 dosing and movement toward Phase 3 readiness. Securing a Japanese patent for its companion diagnostic and signing licensing agreements to enhance its DRP platform support its strategic positioning in precision oncology. The initiation of revenue-generating CLIA services indicates early commercial traction. These developments suggest operational momentum and potential for future product commercialization.

Bear case model:

Allarity Therapeutics reported a net loss and holds a liquidity position with current assets slightly below current liabilities, indicating financial constraints. Negative stockholders' equity raises concerns about compliance with Nasdaq listing requirements, with potential delisting risks. The company relies on debt financing that may impose liquidity and flexibility challenges. Clinical-stage status means product candidates face inherent development and regulatory risks, and the company has yet to establish significant revenue streams beyond initial services.

Moat:

Allarity Therapeutics' moat is centered on its proprietary Diagnostic Response Prediction (DRP) platform and its lead oncology drug candidate, Stenoparib. The granted Japanese patent for the Stenoparib DRP companion diagnostic extends protection through 2039, providing intellectual property barriers. The company's focus on precision oncology and companion diagnostics aligns with a growing trend toward personalized medicine, potentially differentiating its offerings. However, as a clinical-stage company without commercialized products beyond initial CLIA services, its competitive advantage depends heavily on successful clinical development, regulatory approvals, and the ability to scale its diagnostic platform.

Risks overview
Risks summary
Liquidity constraints combined with negative stockholders' equity and debt obligations pose significant risks to Allarity Therapeutics' financial stability and Nasdaq listing status.
Risks details:

• Liquidity and Financing Risks: The company has a current ratio below 1 and negative stockholders' equity as of September 30, 2026, indicating liquidity constraints. It may need to raise additional capital, which could result in dilution and may not be available on favorable terms.
• Nasdaq Listing Compliance Risk: Negative stockholders' equity may lead to non-compliance with Nasdaq's minimum equity requirements, risking delisting which could adversely affect liquidity, market perception, and capital raising ability.
• Debt Obligations: Outstanding notes from Streeterville Capital with maturities in 2027 and significant interest rates may impair liquidity and financing flexibility, with potential acceleration or enforcement actions in case of default.
• Clinical and Regulatory Risks: As a clinical-stage biopharmaceutical company, Allarity faces risks inherent in drug development, including clinical trial outcomes, regulatory approvals, and commercialization challenges.

FINAL FORECAST FOR ALLR

Final take one line
Allarity Therapeutics shows active clinical and diagnostic development with patent protection and initial commercial activity but faces liquidity and Nasdaq listing risks.
Final take 12 to 24 month view

Business trends: Progression of Stenoparib clinical trials, expansion of companion diagnostic platform, and initial revenue generation through CLIA services.
Execution milestones: Advancement toward Phase 3 readiness for Stenoparib, securing patent protections, and signing licensing agreements to enhance precision oncology offerings.
Key risks: Liquidity constraints, negative stockholders' equity risking Nasdaq delisting, debt obligations, and inherent clinical development uncertainties.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

78
LLM visibility overview
LLM Visibility known facts
  • Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology therapeutics and diagnostics.
  • The company is advancing its lead drug candidate, Stenoparib, through clinical trials including Phase 2 dosing in lung cancer and progressing toward Phase 3 readiness.
  • Allarity has developed a Diagnostic Response Prediction (DRP) companion diagnostic platform, with a Japanese patent granted for the Stenoparib DRP companion diagnostic providing protection through 2039.
  • The company signed its first revenue-generating CLIA services deal, indicating initial commercial activity beyond clinical development.
  • Allarity has entered into licensing agreements to enhance its DRP platform and support precision oncology, particularly in breast cancer.
  • The company recorded a net loss of $6.2 million for the quarter ended September 30, 2026, with a basic EPS of -$0.39 for the same period.
  • As of September 30, 2026, Allarity had $14.1 million in cash and cash equivalents and current assets of $26.9 million, with current liabilities of $29.5 million, resulting in a current ratio of 0.91 and a cash ratio of 0.48.
  • The company has outstanding notes from a $20 million financing agreement with Streeterville Capital, with maturities in September 2027 and interest rates of 9% and 5% per annum respectively.
  • Allarity's stockholders' equity was negative as of September 30, 2026, and the company may not meet Nasdaq's minimum stockholders' equity requirement for continued listing, posing a risk of delisting.
  • The company consolidated Allarity Acquisition Corp., a special purpose acquisition company, as a variable interest entity in its financial statements.
  • Recent news coverage includes clinical progress updates, patent grants, licensing agreements, and financial results, reflecting active operational and development milestones.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-10-30 | www.nasdaq.com | Allarity Therapeutics Signs First Revenue-Generating CLIA Services Deal; Stock Down | https://www.nasdaq.com/articles/allarity-therapeutics-signs-first-revenue-generating-clia-services-deal-stock-down
  • N2 | 2026-10-09 | www.nasdaq.com | Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now | https://www.nasdaq.com/articles/heres-why-allarity-therapeutics-inc-allr-great-buy-bottom-stock-now
  • N3 | 2026-09-15 | www.nasdaq.com | Allarity Gets Japanese Patent For Stenoparib DRP Companion Diagnostic; Protection Through 2039 | https://www.nasdaq.com/articles/allarity-gets-japanese-patent-stenoparib-drp-companion-diagnostic-protection-through-2039
  • N4 | 2026-07-22 | www.nasdaq.com | Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? | https://www.nasdaq.com/articles/are-medical-stocks-lagging-allarity-therapeutics-inc-allr-year-0
  • N5 | 2026-06-19 | www.nasdaq.com | Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? | https://www.nasdaq.com/articles/allarity-therapeutics-inc-allr-outperforming-other-medical-stocks-year
  • N6 | 2026-06-03 | www.nasdaq.com | Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? | https://www.nasdaq.com/articles/are-medical-stocks-lagging-allarity-therapeutics-inc-allr-year
  • N7 | 2026-05-18 | www.nasdaq.com | Allarity Records $2 Mln Net Loss In Q1; Initiates Phase 2 Dosing Of Stenoparib In Lung Cancer | https://www.nasdaq.com/articles/allarity-records-2-mln-net-loss-q1-initiates-phase-2-dosing-stenoparib-lung-cancer
  • N8 | 2025-12-10 | www.nasdaq.com | Ascendiant Capital Maintains Allarity Therapeutics (ALLR) Buy Recommendation | https://www.nasdaq.com/articles/ascendiant-capital-maintains-allarity-therapeutics-allr-buy-recommendation-0
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine